Melina Rodriguez: First FDA-Approved VWD Prophylaxis for All Ages
Melina Rodriguez, Founder of Health Evidence Digest, Senior Medical Editor at Precision AQ, shared a post on LinkedIn:
“Von Willebrand Disease Is the Most Common Inherited Bleeding Disorder in the World. In Young Children With Severe Disease, Prophylactic Treatment Has Lacked Any FDA-Approved Option Until Now
On July 2, 2026, the FDA expanded Wilate (von Willebrand Factor/Coagulation Factor VIII Complex Human, Octapharma) approval to include routine prophylaxis in children younger than 6 years with von Willebrand disease, making it the first and only VWF concentrate approved for prophylaxis across all ages and all VWD types.
The Phase 3 WIL-33 trial (NCT04953884; n equals 12; median age 2.0 years; severe VWD) showed a mean total ABR of 4.6 (SD 6.1) during 12 months of prophylaxis; spontaneous ABR 0.9; 98.2% of all bleeds were minor; 95.6% of treated bleeds required only 1 infusion.
This was the first dedicated prospective clinical trial of VWF prophylaxis in children under 6 worldwide.
Here is what VWD is, why prophylaxis matters for young children with severe disease, and what the WIL-33 data shows across VWD types….”
Stay updated with Hemostasis Today.
-
Sep 20, 2026, 05:17Maxime Dely: When ABO Compatibility Isn’t Enough for Safe Transfusion
-
Sep 20, 2026, 04:54William Aird: What Does a Complete History and Physical Really Mean?
-
Sep 20, 2026, 04:34Hons Saurabh Kaushik: Why Uncontrolled LDL Can Be Harmful
-
Sep 20, 2026, 03:58Salih Ehsan: The Complexities of HbF and HbA2
-
Sep 20, 2026, 03:22The Voices of People Living With Bleeding Disorders – EHC
-
Sep 20, 2026, 01:18Sebastian Mafeld: Has 2026 Changed How We Treat Pulmonary Embolism?
-
Sep 20, 2026, 01:16Pall T. Onundarson: DOACs – Monitoring, Tailoring Dose and Identifying Problems
-
Sep 20, 2026, 01:15Thierry Fumeaux: From Efficacy to Effectiveness – The Value of Real-World Evidence
-
Sep 20, 2026, 01:14Said El Shamieh: VEGFA Genetic Variants and Bleeding Risk During Warfarin Therapy